April Hallquist, MD
Orthopaedic Surgery · Corpus Christi, TXNPI 1679894489
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (34.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Arthrex at 51.1% of the total. Reporting peaked in 2019 at $1,871 and has fallen 98.3% since, to $31 in 2025. That places this record below the midpoint for orthopaedic surgery clinicians in TX, where the typical reported total is $4,671.
Across 30 payments — averaging $71.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$1K
- Medinc Of Texas$745
- Stryker$68
- Ferring Pharmaceuticals Inc.$39
- Vertex$38
- Pacira Therapeutics, Inc.$29
- plus $125 from 7 others
What the payments were for
- Travel & lodging$65231%
- Food & beverage$73935%
- Education$74535%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 13 | $1,091 |
| Medinc Of Texas | 1 | $745 |
| Stryker | 1 | $68 |
| Ferring Pharmaceuticals Inc. | 3 | $39 |
| Vertex | 2 | $38 |
| Pacira Therapeutics, Inc. | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Pacira Pharmaceuticals Incorporated | 1 | $24 |
| Smith+Nephew | 1 | $20 |
| BD | 1 | $15 |
| KCI USA, Inc. | 1 | $13 |
| Bioventus LLC | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
How this compares
$2,135 in reported general payments places this provider in the 35th percentile of 1,337 orthopaedic surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 59 | $1,240 |
| Ondansetron OdtOndansetron | 72 | $891 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 54 | $840 |
| Pregabalin | 36 | $629 |
| Naproxen | 54 | $386 |
| Oxycodone Hcl | 36 | $363 |
| Meloxicam | 89 | $353 |
| Gabapentin | 21 | $197 |
| Methylprednisolone | 15 | $153 |
| Tramadol Hcl | 12 | $64 |
| Amoxicillin | 12 | $8 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Corpus Christi
- John MascialeCorpus Christi$825K
- Stephen BurkhartSan Antonio$185.3M
- Kirby HittTemple$9.1M
- Robert GrahamAustin$6.3M
- Richard JonesDallas$6.3M
- Stefan KreuzerHouston$6.2M
- Michael WirthSan Antonio$4.5M
- Stephen IncavoHouston$4.3M
- Thomas EdwardsHouston$4.1M
- James BrodskyDallas$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.